Ethan Zohn is one of the 20 returning contestants to the Survivor game for season 40 of the series and this is his third time on the show. He previously won Survivor: Africa, which was season three, making him the second-earliest returnee for Winners at War behind only Amber Brkich Mariano, who appeared on season two. But he is the earliest winner to return because Amber didnt win until season eight.
Zohn also played on Ambers winning season, All Stars, where he was the sixth person voted out.
Heres what you need to know about the Survivor champ.
Zohn was born and raised in Lexington, Massachusetts, the youngest of three boys (his older brothers are Lenard and Lee, according to the Grassroots Soccer website. Zohn played soccer hes a goalkeeper for Lexington High School and Vassar College, where he majored in biology and marine biology, before going on to play professionally for the Hawaii Tsunami and Cape Cod Crusaders in the U.S. and for the Highlanders FC in Zimbabwe. On the Zimbabwe team, one of Zohns teammates died of AIDS.
In 2008, Zohn used some of his Survivor winnings to found Grassroots Soccer, an organization that aims to educate and prevent HIV and AIDS. Grassroots Soccer sends professional African soccer players into classrooms to teach middle-schoolers about HIV, using a curriculum that combines soccer and academics.
We are really trying to create this generation of HIV-negative kids, said Zohn in a 2008 interview, adding, In Africa, soccer players are heroes. They are like role models, the gods of the community. We train local professional soccer players about HIV and AIDS, and they go into the schools and teach the youths about AIDS prevention.
The program has since expanded to the Dominican Republic and Guatemala.
In 2009, Zohn was diagnosed with a rare type of cancer called CD20-positive Hodgkins lymphoma and shortly thereafter he underwent chemotherapy and stem-cell transplants to fight the disease. He went into remission in April 2010, but the cancer returned in September 2011.
That time around, he had to remain in his New York City apartment at all times when he wasnt going to the doctor and eventually received two rounds of stem-cell transplants from his brother, which were finally successful in early 2013.
I am in remission. Today is a special day, Zohn told CBS News on March 1, 2013. One year ago today I received my brothers stem cells they wiped out my body and infused my brothers stem cells into my body. So if you take my DNA sample, its like my brother.
He added that it had been so hard to be so isolated from everyone.
I have been spending a lot of time with my family, which is very exciting, he said. Ive been in isolation for seven months. I couldnt really leave my apartment unless I was going to the doctor. I just got clearance, so Ive been traveling a little bit, visiting friends and family. I got to hug my nieces and nephews for the first time in a year.
Jenna Morasca won the sixth season of Survivor and it was afterward that she met Zohn. The two began dating in 2003 and were together for a decade. In the time they were together, they appeared on both Survivor: All-Stars and The Amazing Race.
On All-Stars, Morasca famously left the game after nine days because her mothers cancer diagnosis had taken a turn for the worse right before the show began filming. Her mother died a week after she returned home.
After her departure from that season, Morasca told the Pittsburgh Post-Gazette, [Ethans] a great guy, and hes really been there for me. You cant know him and not love him.
In 2011, the two of them appeared in a 20-minute horror short called The Watcher as part of an anthology called Drive-In Horrorshow, which you can watch on YouTube. Then in early 2013, they decided to call it quits.
It is with much consideration and a heavy heart that we are announcing that after 10 years of a loving relationship, the decision was made to move on without each other, the couple said in a joint statement at the time of their breakup. We will carry with us the memories of a relationship grounded in love, laughter, support and friendship. We have experienced some of lifes greatest joys and toughest challenges together, and our decision to be apart can never diminish that. We want to thank everyone for their support and we ask that our privacy be respected as we move forward.
A few years after ending things with Morasca, Zohn began dating New York City interior designer Lisa Heywood. He told People at the time, This is the reason I survived cancer twice to meet Lisa and start a beautiful and healthy new life together.
The two met in 2013 at a Clinton Global Initiative charity event and then two years later, Zohn asked her to marry him on the dock of their New Hampshire lake house, using the ring his late father had given his mother. The two got married in July 2016 in Vermont.
Before the ceremony, they told People that they looked forward to standing together and taking a quiet moment to look at all our family and friends that have supported us along the way. They also said theyre looking forward to getting chubby and growing old together, and the potential we have to make the world a better place by the virtue of being together as one.
Zohnthen predicted that all the happy and sad tears in my life will disappear in her presence.
Ethan Zohn Says Being On Season 40 Of Survivor Is An Absolute Miracle | SURVIVORSurvivor: Africa winner Ethan Zohn tells Sangita Patel that he was a little bit intimidated when he got the call to play on Survivor: Winners at War having had no experience with hidden immunity idols, blindsides and more. Plus, he reveals that hes seven years in remission since being diagnosed with blood cancer at the age of 35. Tune in to the premiere of Survivor: Winners at War on Wednesday, Feb. 12 at 8 p.m. ET/PT on Global. SUBSCRIBE to our channel: https://www.youtube.com/user/ETCanadaOfficial FOLLOW us here: http://www.etcanada.com Facebook: https://www.facebook.com/etcanada Twitter: http://www.twitter.com/etcanada Instagram: http://www.instagram.com/etcanada #Survivor #EthanZohn #SurvivorWinnersAtWar2020-01-15T16:00:06.000Z
In a pre-Winners at War interview with ET Canada, Zohn says he was intimidated to come back after so many years.
To put this in perspective, the last time I played the game was 16 years ago, that was Survivor: All-Stars and the season I won was Survivor: Africa, which was in 2001! This is before hidden immunity idols, clues, ways to get back in the game Ive never done any of that stuff, so as you can imagine, I was a little intimidated and nervous when I got the call to come back for season 40, says Zohn, though he adds that he feels ready to be here because he put in the training and the effort and [he feels] prepared for whats to come.
Zohnalso says that just getting here is an absolute miracle because of what he overcame when he was so sick with cancer.
I remember I was locked in my hospital room, getting my second stem-cell transplant, watching Heroes vs Villains, praying to myself that Id be alive long enough that Id be able to play again I just wanted to get healthy enough so I could come back and play Survivor. I knew there had to be an all-winners season coming at some point and I wanted to be part of that.
Survivor: Winners at War airs Wednesdays at 8 p.m. ET/PT on CBS.
READ NEXT: Meet the Survivor: Winners at War Cast
More here:
Ethan Zohn on Survivor: 5 Fast Facts You Need to Know - Heavy.com
- BIORESTORATIVE THERAPIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K) - Marketscreener.com - March 29th, 2023
- Induced Pluripotent Stem Cell for the Study and Treatment of ... - Hindawi - December 3rd, 2022
- What Happens When Everyone Realises We Can Live Much Longer? We May Find Out As Soon As 2025 - Forbes - December 3rd, 2022
- INTERNATIONAL STEM CELL CORP Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - Marketscreener.com - November 17th, 2022
- 3D Cell Culture Market stands at revenue of US$ 1.15 Bn in 2022, and is predicted to surge at a CAGR of 9.8% to hit worth of US$ 2.67 Bn during... - November 17th, 2022
- YUBO INTERNATIONAL BIOTECH LTD Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - Marketscreener.com - November 17th, 2022
- ACTINIUM PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION (form 10-Q) - Marketscreener.com - November 17th, 2022
- Top 10 Best Stem Cell Supplement Brands - Healthtrends - June 26th, 2022
- How Does Stem Cell Therapy Work and What Are the Risks? | ISCRM - June 26th, 2022
- Stem Cell Wellness Kit - June 26th, 2022
- Kangstem Biotech withdraws trial application for stem cell-based osteoarthritis treatment - KBR - June 26th, 2022
- Global Human Embryonic Stem Cell Market to be Driven by the Rapid Technological Advancements in the Forecast Period of 2022-2027 Designer Women -... - June 26th, 2022
- Sana Biotechnology Announces Multiple Preclinical Data Presentations to Showcase Its Hypoimmune Platform, Including in Type 1 Diabetes, at the... - June 26th, 2022
- Efficient terminal erythroid differentiation requires the APC/C cofactor Cdh1 to limit replicative stress in erythroblasts | Scientific Reports -... - June 26th, 2022
- Propanc Biopharma's CSO Hails Dostarlimab's Impressive Results Whilst Acknowledging More Work to Be Done in the Fight Against Cancer - Business Wire - June 26th, 2022
- Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including... - June 26th, 2022
- 10 Years of Immunotherapy: Advances, Innovations, and Better Patient Outcomes - Targeted Oncology - June 26th, 2022
- Embryonic Stem Cell Research: An Ethical Dilemma - January 30th, 2022
- Skeletal Muscle Cell Induction from Pluripotent Stem Cells - January 30th, 2022
- mRNA COVID-19 Vaccine Effectiveness in the Immunocompromised - Medscape - January 30th, 2022
- MaaT Pharma Announces Positive Interim Engraftment Data for Oral Formulation MaaT033 Allowing Early Termination of Phase 1b CIMON Study - Business... - January 30th, 2022
- European Commission Approves Merck's KEYTRUDA (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following... - January 30th, 2022
- Targeted Therapy Innovator Foresees New Paradigms in Breast Cancer - OncLive - January 30th, 2022
- Global Circulating Tumor Cells (CTC) Market Growing Demand, Future Trends, Competitive Regions and Forecast 2021 to 2027 The Oxford Spokesman - The... - January 30th, 2022
- Adipose derived mesenchymal stem cell secretome formulation as a biotherapeutic to inhibit growth of drug resistant triple negative breast cancer |... - December 8th, 2021
- All at-risk TN-bound travellers test Covid negative - The New Indian Express - December 8th, 2021
- Good Stocks To Invest In Right Now? 4 Health Care Stocks To Check Out - FW Business - December 8th, 2021
- Pandemic lockdown declined emotional well-being for adults with hearing, vision loss: Study - ETHealthworld.com - December 8th, 2021
- Impact of microbial contamination of haematopoietic stem cells on post-transplant outcomes: A retrospective study from tertiary care centre in India -... - August 17th, 2021
- Longeveron: Time to Buy the Di - GuruFocus.com - August 17th, 2021
- The latest on the Covid-19 pandemic in the US: Live updates - CNN - August 17th, 2021
- How this Holocaust refugee beat Covid-19 against all odds J. - The Jewish News of Northern California - August 17th, 2021
- Trade-offs among transport, support, and storage in xylem from shrubs in a semiarid chaparral environment tested with structural equation modeling -... - August 17th, 2021
- Oklahoma 10-year-old in remission after being diagnosed with rare form of leukemia 2 years ago - KFOR Oklahoma City - July 21st, 2021
- Covid: There's a serious problem with how we are testing people for the virus Neale Hanvey MP - The Scotsman - July 21st, 2021
- Profilin 1 Protein and Its Implications for Cancers - Cancer Network - July 21st, 2021
- Homing Technology Delivers Therapy to Cancerous Bone - The Scientist - July 21st, 2021
- Developmental Interest in Allogeneic PlacentaDerived Cell Therapies Expands - OncLive - July 21st, 2021
- Triple negative breast cancer and non-small cell lung cancer: Clinical challenges and nano-formulation approaches - DocWire News - July 21st, 2021
- The World's First Lab-Grown Foie Gras Could Solve This Major Concern - Mashed - July 21st, 2021
- KEYTRUDA (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Showed Statistically Significant Event-Free... - July 21st, 2021
- Human Mesenchymal Stem Cells (hMSC) Market Size 2021 | Global Trends, Business Overview, Challenges, Opportunities and Forecast to 2027 The Bisouv... - March 3rd, 2021
- [Full text] An Update on the Molecular Pathology of Metaplastic Breast Cancer | BCTT - Dove Medical Press - March 3rd, 2021
- 4D Pharma Appointments Paul Maier to the Board as Non-Executive Director - Business Wire - March 3rd, 2021
- Investigative Interventions Gain Ground in GVHD - OncLive - March 3rd, 2021
- Combination Regimens for Multiple Myeloma Show Efficacy in the Transplant-Ineligible Population, According to Dingli - Targeted Oncology - March 3rd, 2021
- Martin Makes Sense of the Rapidly Evolving MCL Treatment Paradigm - OncLive - March 3rd, 2021
- Hoth Therapeutics Expands License Agreement to Include Innovative Cancer and Anaphylactic Treatment - BioSpace - March 3rd, 2021
- Health Matters; Inflammation with Dr. Baumgartner [PODCAST] - WJON News - February 14th, 2021
- G1 Therapeutics gains first FDA nod with myelopreservation therapy Cosela | 2021-02-12 - BioWorld Online - February 14th, 2021
- Kris Gopalakrishnan on innovation - Fortune India - February 14th, 2021
- Change is coming, and at an ever-accelerating pace - Al Jazeera English - January 12th, 2021
- MCL Landscape Adapts to Changes After CAR T-Cell Therapy Approval - OncLive - January 9th, 2021
- 5 questions facing gene therapy in 2021 - BioPharma Dive - January 9th, 2021
- RNA molecules are masters of their own destiny - MIT News - January 9th, 2021
- Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market: Industry Analysis and Forecast (2019-2026): By indication type, treatment type,... - January 9th, 2021
- Harpoon Therapeutics : Clin Cancer Res 2021; OnlineFirst version Jan 6, 2021 - Marketscreener.com - January 9th, 2021
- Synthetic lethality across normal tissues is strongly associated with cancer risk, onset, and tumor suppressor specificity - Science Advances - January 5th, 2021
- Versiti Blood Centers and Noodles & Company Serve Up Thanks to Blood Donors - PRNewswire - January 5th, 2021
- January 2021: 2020 Papers of the Year - Environmental Factor Newsletter - January 5th, 2021
- Ozone in the air is bad for birds - Massive Science - January 5th, 2021
- How good are the COVID-19 vaccines? - Massive Science - January 5th, 2021
- Stem cells from cord blood can now be used across many conditions: Mayur Abhaya, MD & CEO, LifeCell Internat.. - ETHealthworld.com - December 28th, 2020
- Allogeneic SCT Benefits Children and Adolescents With Relapsed Anaplastic Large Cell Lymphoma - OncLive - December 28th, 2020
- CalvinAyre.com's most read life stories of 2020 - CalvinAyre.com - December 28th, 2020
- Coronavirus | Over 6,000 travellers from U.K. traced across States - The Hindu - December 28th, 2020
- Exosomes act as messengers and decoys to save healthy cells from viral infection - Massive Science - December 28th, 2020
- Celtics adjust to two-game series designed to reduce team travel - The Boston Globe - December 28th, 2020
- Experts Reflect on Most Impactful FDA Moves of 2020 in Solid Tumors, Hematologic Malignancies - Targeted Oncology - December 28th, 2020
- FDA Resumes eIND Approval for Severe-to-Critical COVID-19 Patients Use of Vyrologix (leronlimab) Following Full Enrollment in CytoDyn's Phase 3 Trial... - December 28th, 2020
- Magenta Therapeutics Announces Commencement of First Phase 2 Clinical Trial of MGTA-145 for Stem Cell Mobilization, Oral Presentation of MGTA-145... - December 12th, 2020
- Daratumumab Regimen Shows Promise in Transplant-Eligible Patients With Newly Diagnosed Myeloma - Targeted Oncology - December 12th, 2020
- HSCT Found Potentially Curative for Some T-Cell Lymphoma Patients - Cancer Therapy Advisor - December 12th, 2020
- Researchers Trace the Origin of Blood Cancer to Early Childhood, Decades before Diagnosis - Yahoo Finance - December 12th, 2020
- ALLO-715, Off-the-Shelf CAR T-Cell Therapy, Produces Early Promise in Multiple Myeloma - Cancer Network - December 12th, 2020
- BeiGene Announces the Approval in China of BLINCYTO (Blinatumomab) for Injection for Adult Patients with Relapsed or Refractory B-Cell Precursor Acute... - December 12th, 2020
- Flintshire youngster goes the extra mile to raise funds for Lymphoma Action | The Leader - LeaderLive - December 12th, 2020
- Meat-Tech Agrees to Acquire Cultured Fat Pioneer 'Peace of Meat' - PRNewswire - December 12th, 2020
- Stem Cell Manufacturing Market Size, Overview with Detailed Analysis, Competitive landscape, Forecast to 2027 - Cheshire Media - December 12th, 2020
- Rocket Pharmaceuticals Presents Positive Clinical Data from its Fanconi Anemia and Leukocyte Adhesion Deficiency-I Programs at the 62nd American... - December 12th, 2020